Sverige - svenska - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - ritonavir - filmdragerad tablett - 100 mg - ritonavir 100 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - lopinavir; ritonavir - filmdragerad tablett - 200 mg/50 mg - lopinavir 200 mg aktiv substans; ritonavir 50 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - lopinavir; ritonavir - filmdragerad tablett - 200 mg/50 mg - ritonavir 50 mg aktiv substans; lopinavir 200 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - flukonazol - kapsel, hård - 100 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; flukonazol 100 mg aktiv substans - flukonazol

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - lamotrigin - tuggtablett/dispergerbar tablett - 100 mg - lamotrigin 100 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - sildenafilcitrat - filmdragerad tablett - 100 mg - laktosmonohydrat hjälpämne; sildenafilcitrat 140,48 mg aktiv substans - sildenafil

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - sertralinhydroklorid - filmdragerad tablett - 100 mg - sertralinhydroklorid 112 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

mylan s.a.s - ritonavir - hiv-infektioner - antivirala medel för systemisk användning - ritonavir är indicerat i kombination med andra antiretrovirala medel för behandling av hiv 1-infekterade patienter (vuxna och barn 2 år och äldre).

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiska medel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - lakosamid - epilepsi - antiepileptika, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.